(b)(6) 2014 - subject underwent her third neurostimulator replacement procedure.The rns system consists of a neurostimulator, a connected depth lead (dl-330-10) and a cortical strip lead (cl-315-10).(b)(6) 2015 - subject noted a small depression in the area of the neurostimulator implant.It was initially tender to touch and cyst-like, then it "popped", releasing waxy material and now leaving a depression at the site of the previous cyst.The depression is still there and cultures positive for staph aureus.Antibiotic treatment was started.(b)(6) 2015 - the ferrule was replaced to allow treatment of the infection.In addition antibiotics were introduced into the incision site as an additional measure to treat the infection.The rns system remains implanted and both therapy and detection are enabled.
|
(b)(4), this patient is part of the clinical trial.Udi - na.(b)(4) 2015 (b)(4) voided this complaint.There was no reported product malfunction and no indication the product contributed to the infection.Infections are anticipated when performing craniotomy procedures.(b)(4) 2015 neuropace, inc.Reevaluated this record.Based on internal review of the fda regulations, guidance document (draft guidance for industry and food and drug administration staff), and internal procedures, neuropace, inc.Determined that complaints associated with incision site infections are reportable.These past events show no indication that the product caused the infection and there is no indication of product failure.The rns system remains implanted and is programmed for detection and therapy.Sterility record review performed.No evidence of factors that could have caused or contributed to the reported event.All sterilization results met requirements as specified in the specifications.Product remains implanted.
|